Otolog kök hücre nakli yapılan multiple myelom ve lenfoma hastalarında kök hücre dozunun ve beden kitle indeksinin engrafman üzerindeki etkisi
Küçük Resim Yok
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Çalışmamızda; OKHN yapılmış olan lenfoma veya MM tanılı hastalarda, CD34 (+) kök hücre dozunun ve hastanın BKİ'nin, engrafman süresi ve nakil sonrası hastanede kalış süresi üzerindeki etkisini göstermeyi ve sonuçlarımızı literatür verileri ile karşılaştırmayı amaçladık. Materyal ve Metot: İnönü Üniversitesi Turgut Özal Tıp Merkezi Kemik İliği Nakil Ünitesi'nde lenfoma ve MM tanısı ile Ocak 2015–Kasım 2019 tarihleri arasında OHKN yapılmış olan 302 hastanın verileri retrospektif olarak hastane bilgi yönetim sistemi ve hasta dosyaları üzerinden incelendi. Bulgular: Hastaların demografik verileri, BKİ, verilen CD34 (+) kök hücre dozu, trombosit-nötrofil engrafman süresi, nakil sonrası hastanede kalış süresi incelendi. Tüm hasta gruplarında trombosit engrafmanı ortalama 14.06±4.4 gün, nötrofil engrafmanı ortalama 11.5±2.6 gün, hastanede kalış süresi ise ortalama 16±4.0 gün olarak saptandı. Hastalar CD34 (+) kök hücre dozuna göre <3×106/kg, 3-5×106/kg ve >5×106/kg olarak üç gruba ayrıldığında, infüze edilen CD34 (+) kök hücre dozu arttıkça nötrofil-trombosit engrafman süresinde ve hastanede kalış süresinde kısalma tespit edildi (p=0.001). BKİ'ne göre hastalar zayıf, normal, fazla kilolu, obez olarak dört gruba ayrılarak karşılaştırıldığında, BKİ ile engrafman süresi ve hastanede kalış süresi arasında anlamlı istatistiksel sonuç elde edilmedi (p>0.05). Sonuç: OKHN yapılan hastalarda, hastaya verilen CD34 (+) kök hücre dozu arttıkça engrafman süresi ve nakil sonrası hastanede kalış süresi kısalırken (p=0.001), hastaların BKİ ile engrafman süresi ve hastanede kalış süresi arasında anlamlı ilişki saptanmadı (p>0.05). Anahtar Kelimeler: BKİ, CD34 (+) Kök Hücre Dozu, Engrafman, OKHN
Aim: In this study we planned to retrospectively show relationship between number of CD34 (+) stem cell and body mass index how affect duration of hospital stay with engraftment time at the patient who get auto-HSCT for multiple myeloma or lymphoma. Material and Method: We studied 302 MM patients and lymphoma patients who get auto-HSCT at Inonu University Turgut Özal Medical Center at Bone Marrow Transplant Unit between January 2015-November 2019. We research that patients retrospectively via hospital data server and patients special files. Results: Patients demographic datas, BMI, CD34 (+) stem cell dosage for treatment, neutrophil and platelet engraftment time as well as duration after transplantation were examined. When all patient groups were evaluated, the mean platelet engraftment was 14.06±4.4days, the mean neutrophil engraftment was 11.5±2.6 days and that patients mean hospital stay was 16±4 days.We divided patients into three groups as <3×106/kg, 3-5×106/kg and >5×106/kg according to the CD34 (+) stem cell dose given to the patient.The dose of infused CD34 (+) stem cell increasing directly affected shortening of the duration neutrophil-platelet engraftment time and with length of hospital stay (p=0.001). According to the BMI, when the patients were divided into four groups as weak, normal, overweight and obese no significant statistical results were obtained between BMI and engraftment time and length of hospital stay (p>0.05). Conclusion: In patients with OKHN, while CD34 (+) stem cell dose increased, the duration of engraftment and hospital stay after transplantation decreased (p=0.001), there was no significant relationship between BMI and duration of engraftment and hospital stay (p>0.05). Key Words: Auto-HSCT, BMI, CD34 (+) Stem Cell Dose, Engraftment
Aim: In this study we planned to retrospectively show relationship between number of CD34 (+) stem cell and body mass index how affect duration of hospital stay with engraftment time at the patient who get auto-HSCT for multiple myeloma or lymphoma. Material and Method: We studied 302 MM patients and lymphoma patients who get auto-HSCT at Inonu University Turgut Özal Medical Center at Bone Marrow Transplant Unit between January 2015-November 2019. We research that patients retrospectively via hospital data server and patients special files. Results: Patients demographic datas, BMI, CD34 (+) stem cell dosage for treatment, neutrophil and platelet engraftment time as well as duration after transplantation were examined. When all patient groups were evaluated, the mean platelet engraftment was 14.06±4.4days, the mean neutrophil engraftment was 11.5±2.6 days and that patients mean hospital stay was 16±4 days.We divided patients into three groups as <3×106/kg, 3-5×106/kg and >5×106/kg according to the CD34 (+) stem cell dose given to the patient.The dose of infused CD34 (+) stem cell increasing directly affected shortening of the duration neutrophil-platelet engraftment time and with length of hospital stay (p=0.001). According to the BMI, when the patients were divided into four groups as weak, normal, overweight and obese no significant statistical results were obtained between BMI and engraftment time and length of hospital stay (p>0.05). Conclusion: In patients with OKHN, while CD34 (+) stem cell dose increased, the duration of engraftment and hospital stay after transplantation decreased (p=0.001), there was no significant relationship between BMI and duration of engraftment and hospital stay (p>0.05). Key Words: Auto-HSCT, BMI, CD34 (+) Stem Cell Dose, Engraftment
Açıklama
Anahtar Kelimeler
İç Hastalıkları, Internal diseases
